Technically Speakin...
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.27 0.00 | 0.00%
06/04/12 - 01:03 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.30 | 0.58 | 0.98 |
| Price to Sales (TTM) | 192.18 | 4.62 | 1.42 |
| Price to Book (MRQ) | 1.02 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 1.04 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -3.70 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -2.80 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 71.40 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 19.30 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | -33.18 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 17.16 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.40 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 5.60 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.02 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.08 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 49.60 | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -1,687.23 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -54.75 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -24.50 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -33.60 | 2.20 | 2.50 |
| Return on Investment (TTM) | -28.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -36.80 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 4,064.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -222,489.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 0.60 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with HEB
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Usermaybe will work?
- UserTornado Portfolio
- Userjimb Portfolio 1
- Usergenomics
- User5for5
- Userjoe today
- UserNathan88
Latest HEB Headlines from TheStreet
- Hemisphrex Biopharma Announces Fiscal 2010 Year Results 03.29.11 | 01:03 pm
- Hemispherx Biopharma Reports On Annual Stockholder Meeting 03.22.11 | 02:03 pm
- Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted 03.07.11 | 02:03 pm
- Chronix Biomedical And Hemispherx Biopharma Jointly File Patent Application For A Blood Test For Chronic Fatigue Syndrome (CFS) 03.03.11 | 10:03 am
- Hemispherx Biopharma Annual Meeting Set 02.24.11 | 08:02 am
- Hemispherx Biopharma, Inc. Announces It Has Scheduled Its 2010 Annual Stockholders' Meeting To Occur On March 17, 2011 In Remediation Of Notice From The NYSE Amex Of Non-Compliance With The Requirement To Hold Its Annual Stockholders' Meeting By The End Of 2010 02.23.11 | 01:02 pm
- Hemispherx Biopharma Appoints Senior Pharma Executive To Key Manufacturing Position 02.17.11 | 10:02 am
- Hemispherx Biopharma Announces US District Court Grants Final Approval Of Settlement Of Securities Class Actions 02.17.11 | 08:02 am
- FDA Authorizes Alferon LDO Clinical Study For Treatment And Prevention Of Influenza 01.04.11 | 10:01 am
- Hemispherx Biopharma, Inc. To Restate 2009 Financial Statements 12.28.10 | 04:12 pm
Press Releases for HEB
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
